A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib ( BRUIN ) versus standard of care ( SCHOLAR ‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor

Documenti analoghi

• Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
  di: Antonio Pinto, et al.
  Pubblicazione: (2024)
• Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe
  di: Enver Aydilek, et al.
  Pubblicazione: (2024)
• Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report
  di: Anna Nikkarinen, et al.
  Pubblicazione: (2024)
• Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53‐mutant mantle cell lymphoma
  di: Manik Uppal, et al.
  Pubblicazione: (2025)
• Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
  di: Alessandro Broccoli, et al.
  Pubblicazione: (2025)